Author
Bicheng Liu
Other affiliations: Southwest University
Bio: Bicheng Liu is an academic researcher from Southeast University. The author has contributed to research in topics: Renal function & Kidney disease. The author has an hindex of 3, co-authored 4 publications receiving 1447 citations. Previous affiliations of Bicheng Liu include Southwest University.
Papers
More filters
TL;DR: The prevalence of chronic kidney disease in China was high in north and southwest and southwest regions compared with other regions, and economic development was independently associated with the presence of albuminuria.
1,588 citations
Peking University1, Zhengzhou University2, Anhui Medical University3, First Affiliated Hospital of Xinjiang Medical University4, Huazhong University of Science and Technology5, Zhejiang University6, Fujian Medical University7, China Three Gorges University8, Kunming Medical University9, Shanghai Jiao Tong University10, Harbin Medical University11, Lanzhou University12, Shandong University13, Second Military Medical University14, Shanxi Medical University15, The University of Nottingham Ningbo China16, Southeast University17, Hebei Medical University18, Guangxi Medical University19, Fudan University20
TL;DR: A nationwide, cross-sectional survey of adult patients who were admitted to hospital in 2013 in academic or local hospitals from 22 provinces in mainland China aimed to evaluate the burden of AKI and assess the availability of diagnosis and treatment and found that 1·4-2·9 million people with AKI were admitted in China in 2013.
292 citations
TL;DR: Delayed AKI recognition and being located in northern China were independent risk factors for in-hospital mortality, and referral to nephrology providers was an independent protective factor.
49 citations
01 Jan 2012
1 citations
Cited by
More filters
TL;DR: Screening and intervention can prevent chronic kidney disease, and where management strategies have been implemented the incidence of end-stage kidney disease has been reduced, but awareness of the disorder remains low in many communities and among many physicians.
3,207 citations
TL;DR: The burden of CKD was much higher than expected for the level of development, whereas the disease burden in western, eastern, and central sub-Saharan Africa, east Asia, south Asia, central and eastern Europe, Australasia, and western Europe was lower than expected.
2,370 citations
TL;DR: CKD has a high global prevalence with a consistent estimated global CKD prevalence of between 11 to 13% with the majority stage 3, and future research should evaluate intervention strategies deliverable at scale to delay the progression of CKD and improve CVD outcomes.
Abstract: © 2016 Hill et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Chronic kidney disease (CKD) is a global health burden with a high economic cost to health systems and is an independent risk factor for cardiovascular disease (CVD). All stages of CKD are associated with increased risks of cardiovascular morbidity, premature mortality, and/or decreased quality of life. CKD is usually asymptomatic until later stages and accurate prevalence data are lacking. Thus we sought to determine the prevalence of CKD globally, by stage, geographical location, gender and age. A systematic review and meta-analysis of observational studies estimating CKD prevalence in general populations was conducted through literature searches in 8 databases. We assessed pooled data using a random effects model. Of 5,842 potential articles, 100 studies of diverse quality were included, comprising 6,908,440 patients. Global mean(95%CI) CKD prevalence of 5 stages 13.4%(11.7-15.1%), and stages 3-5 was 10.6%(9.2-12.2%). Weighting by study quality did not affect prevalence estimates. CKD prevalence by stage was Stage-1 (eGFR>90+ACR>30): 3.5% (2.8-4.2%); Stage-2 (eGFR 60-89+ACR>30): 3.9% (2.7-5.3%); Stage-3 (eGFR 30-59): 7.6% (6.4-8.9%); Stage-4 = (eGFR 29-15): 0.4% (0.3-0.5%); and Stage-5 (eGFR<15): 0.1% (0.1-0.1%). CKD has a high global prevalence with a consistent estimated global CKD prevalence of between 11 to 13% with the majority stage 3. Future research should evaluate intervention strategies deliverable at scale to delay the progression of CKD and improve CVD outcomes.
2,321 citations
TL;DR: The findings show the prevalence of kidney disease on admission and the development of AKI during hospitalization in patients with COVID-19 is high and is associated with in-hospital mortality, and clinicians should increase their awareness of kidney patients with severe CO VID-19.
1,994 citations
TL;DR: Stroke and ischaemic heart disease were the leading causes of death and DALYs at the national level in China in 2017, and China has made substantial progress in reducing the burden of many diseases and disabilities.
1,874 citations